The Lancet Infectious Diseases in conversation with
The Lancet Group
18 episodes
3 weeks ago
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
All content for The Lancet Infectious Diseases in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
Lilian Tina Minja and Norbert Heinrich on TB drug development
The Lancet Infectious Diseases in conversation with
29 minutes
4 months ago
Lilian Tina Minja and Norbert Heinrich on TB drug development
Lilian Tina Minja and Norbert Heinrich discuss a pair of trials they recently published in The Lancet Infectious Diseases, ‘A prospective, randomised, open label phase 2b dose-finding trial of sutezolid in combination with bedaquiline, delamanid and moxifloxacin for pulmonary tuberculosis: SUDOCU’ and ‘A prospective, randomised, open label phase 2b dose-finding trial of delpazolid in combination with bedaquiline, delamanid and moxifloxacin for pulmonary tuberculosis: DECODE’ and the wider imp...
The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
